Future treatments for hereditary hemorrhagic telangiectasia - Université Grenoble Alpes Accéder directement au contenu
Article Dans Une Revue Orphanet Journal of Rare Diseases Année : 2020

Future treatments for hereditary hemorrhagic telangiectasia


Abstract Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000–8000 individuals worldwide. This rare disease is characterized by various vascular defects including epistaxis, blood vessel dilations (telangiectasia) and arteriovenous malformations (AVM) in several organs. About 90% of the cases are associated with heterozygous mutations of ACVRL1 or ENG genes, that respectively encode a bone morphogenetic protein receptor (activin receptor-like kinase 1, ALK1) and a co-receptor named endoglin. Less frequent mutations found in the remaining 10% of patients also affect the gene SMAD4 which is part of the transcriptional complex directly activated by this pathway. Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, recent progress has been made using drugs that target VEGF (vascular endothelial growth factor) and the angiogenic pathway with the use of bevacizumab (anti-VEGF antibody). Furthermore, several exciting high-throughput screenings and preclinical studies have identified new molecular targets directly related to the signaling pathways affected in the disease. These include FKBP12, PI3-kinase and angiopoietin-2. This review aims at reporting these recent developments that should soon allow a better care of HHT patients.

Dates et versions

hal-03925661 , version 1 (05-01-2023)



Florian Robert, Agnès Desroches-Castan, Sabine Bailly, Sophie Dupuis-Girod, Jean-Jacques Feige. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 2020, 15 (1), pp.4. ⟨10.1186/s13023-019-1281-4⟩. ⟨hal-03925661⟩
27 Consultations
0 Téléchargements



Gmail Mastodon Facebook X LinkedIn More